Elevated U.S. Treasury yields near 5.3% on the 10-year note, driven by the Federal Reserve’s September 2026 rate hike and geopolitical pressures on energy prices, have raised discount rates and compressed valuations for growth-oriented issuers, contributing to Q3 IPO postponements and a softer Nasdaq IPO Pulse. Despite this, 2026 equity issuance has already set records at roughly $431 billion year-to-date through IPOs, follow-ons, and related offerings, fueled by AI infrastructure demand and strong investor absorption of recent deals. A deep pipeline of candidates, including scheduled October listings such as Iambic Therapeutics and City Therapeutics plus potential larger filings like Anthropic, supports continued activity through year-end, while Goldman Sachs projects $175 billion in 2027 IPO volume. Traders weigh these rate-sensitive dynamics against resilient earnings growth and sector momentum.